The evolving role of interventional pain management in oncology

Journal of Supportive Oncology

Volumn 2, Issue 6, 2004, Pages 491-503

  Sloan, Paul A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; BUPIVACAINE; CLONIDINE; FENTANYL; HYDROMORPHONE; KETAMINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; METHADONE; MIDAZOLAM; MORPHINE; NARCOTIC ANALGESIC AGENT; NEOSTIGMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; PETHIDINE; PHENOL; STEROID; SUFENTANIL CITRATE;

ABDOMINAL CANCER; ANALGESIA; ANALGESIC ACTIVITY; BRADYCARDIA; BRAIN DEPTH STIMULATION; CANCER ADJUVANT THERAPY; CANCER PAIN; CATHETER INFECTION; CELIAC PLEXUS; CELL TRANSPLANTATION; CEREBROSPINAL FLUID FISTULA; CHROMAFFIN CELL; CHRONIC PAIN; CLINICAL TRIAL; COLON CANCER; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE RESISTANCE; DORSAL RHIZOTOMY; DOSE CALCULATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EPIDURAL ABSCESS; EPIDURAL CATHETER; GYNECOLOGIC CANCER; HEADACHE; HEALTH CARE COST; HUMAN; HYPOGASTRIC PLEXUS; INFUSION PUMP; INTERVENTIONAL RADIOLOGY; META ANALYSIS; NAUSEA; NERVE BLOCK; NEUROANATOMY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PANCREAS CANCER; PELVIS CANCER; PERCUTANEOUS VERTEBROPLASTY; PRURITUS; QUALITY OF LIFE; REVIEW; SEDATION; SPINAL ANESTHESIA; SPINAL CORD STIMULATION; THALAMOTOMY; TREATMENT FAILURE; URINE RETENTION; URTICARIA; VOMITING;

ANALGESICS; CATHETERIZATION; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PAIN; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 11944270367     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Portenoy RK. Cancer pain: epidemiology and syndromes. Cancer 1989;63(11 suppl):2298-2307.
2. Schug SA, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990;5:27-32.
3. Ventafridda V, Tamburini M, Caraceni A, DeConno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987;59:850-856.
4. Sloan PA, Melzack R. Long-term patterns of morphine dosage and pain intensity among cancer patients. Hosp J 1999;14:35-47.
5. Sloan PA, Hodes J, John W. Radiosurgical pituitary ablation for cancer pain. J Palliat Care 1996;12:51-53.
6. Lema MJ. Invasive procedures for cancer pain. Pain Clin Updat 1998;6:1-4.
7. Hassenbusch SJ. Surgical management of cancer pain. Neurosurg Clin N Am 1995;6:127-134.
8. Staats PS. The pain-mortality link: unraveling the mysteries. In: Payne R, Patt RB, Hill CS, eds. Progress in Pain Research and Management. Vol. 12. Seattle, Wa: IASP Press; 1998:145-156.
9. Abram SE, ed. Pain Management. Philadelphia, Pa: Churchill Livingstone; 1998. Miller RD, ed. Atlas of Anesthesia; vol 6.
10. Patt RB. Cancer Pain. Philadelphia, Pa: Lippincott Co.; 1993.
11. Waldman SD. Interventional Pain Management. Phildelphia, Pa: Saunders Co.; 2001.
12. de Leon-Casasola OA. Critical evaluation of chemical neurolysis of the sympathetic axis for cancer pain. Cancer Control 2000;7:142-148.
13. Jain S, Ketchedjian AG. Anterior approach to the celiac plexus block. Pain Digest 1995;5:264-267.
14. Wong GY, Brown DL. Celiac plexus block for cancer pain. In: Utney W, ed. Techniques in Regional Anesthesia and Pain Management. Vol. 1. Philadelphia, Pa: W.B. Saunders; 1997.
15. Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291:1092-1099.
16. Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995;80:290-295.
17. Davies DD. Incidence of major complications of neurolytic coeliac plexus block. J R Soc Med 1993;86:264-266.
18. Plancarte R, de Leon-Casasola OA, El-Helaly M, Allenda S, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 1997;22:562-568.
19. Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965;150:971-999.
20. Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology 1979;50:149-151.
21. Miguel R. Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control 2000;7:149-156.
22. Walker SM, Goudas LC, Cousins MJ, Carr DB. Combination spinal analgesic chemotherapy: a systematic review. Anesth Analg 2002;95:674-715.
23. Stoelting RK, Miller RD. Spinal and epidural anesthesia. In: Stoelting RK, Miller RD, eds. Basics of Anesthesia. Philadelphia, Pa: Churchill Livingstone; 2000:168-195.
24. Krames ES. Practical issues when using neuraxial infusion. Oncology (Huntingt) 1999;13(5 suppl 2):S37-S44.
25. Sloan PA. Anesthesiologic Interventions for the management of cancer pain. In: Schmidt RF, Willis WD, eds. Encyclopedic Reference of Pain. Heidelberg, Germany: Springer-Verlag. In Press.
26. Alkerman B, Arwestrom E, Post C. Local anesthetics potentiate spinal morphine antinociception. Anesth Analg 1988;67:943-948.
27. Nitescu P, Dahm P, Appelgren L, Curelaru I. Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of 'refractory' nonmalignant pain. Clin J Pain 1998;14:17-28.
28. Samuelsson H, Malmberg F, Eriksson M, Hedner T. Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage 1995;10:105-112.
29. Gilmer-Hill HS, Boggan JE, Smith KA, et al. Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer. Surg Neurol 1999;51:6-11.
30. Gilmer-Hill H, Boggan JE, Smith KA, Wagner FC Jr. Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Surg Neurol 1999;51:12-15.
31. Rauck RL, Cherry D, Boyer MF, et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 2003;4:441-447.
32. Mercadante S. Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. J Pain Symptom Manage 1994;9:201-207.
33. Nitescu P, Sjoberg M, Appelgren L, Curelaru I. Complications of intrathecal opioids and bupivacaine in the treatment of 'refractory' cancer pain. Clin J Pain 1995;11:45-62.
34. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002;20:4040-4049.
35. Smith TJ, Coyne PJ. How to use implantable intrathecal drug delivery systems for refractory cancer pain. J Support Oncol 2003;1:73-76.
36. Bennett G, Burchiel K, Buchser E, et al. Clinical guidelines for intraspinal infusion: report of an expert panel. Poly Analgesic Consensus Conference 2000. J Pain Symptom Manage 2000;20:S37-S43.
37. Mercadante S, Villari P, Ferrara P, Arcuri E. Local anesthetic switching for intrathecal tachyphylaxis in cancer patients with pain. Anesth Analg 2003;97:187-189.
38. Gestin Y, Vainio A, Pegurier AM. Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer. Acta Anaesthesiol Scand 1997;41:12-17.
39. Ubogu EE, Lindenberg JR, Werz MA. Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection. Reg Anesth Pain Med 2003;28:470-474.
40. Bedder MD, Burchiel K, Larson A. Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 1991;6:368-373.
41. Hillner BE, Smith T Coyne PJ, et al. Preliminary estimates of the cost effectiveness ratio of implantable drug delivery systems compared to comprehensive medical management in patients with refractory cancer pain. In: Program/Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, III. Abstract 2137.
42. Lazorthes Y, Sagen J, Sallerin B, et al. Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study. Pain 2000;87:19-32.
43. Cerda-Olmedo G, De Andres J, Moliner S. Management of progressive pain in a patient with intramedullary chordoma of the spine. Clin J Pain 2002;18:128-131.
44. Krames ES. Interventional pain management. Med Clin North Am 1999;83:787-808.
45. Vranken JH, van der Vegt MH, Zuurmond WW, Pijl AJ, Dzoljic M. Continuous brachial plexus block at the cervical level using a posterior approach in the management of neuropathic cancer pain. Reg Anesth Pain Med 2001;26:572-575.
46. Vranken JH, van der Vegt MH, Ubags LH, Pijl AJ, Dzoljic M. Continuous sacral nerve root block in the management of neuropathic cancer pain. Anesth Analg 2002;95:1724-1725.
47. Amesbury B, O'Riordan J, Dolin S. The use of interpleural analgesia using bupivacaine for pain relief in advanced cancer. Palliat Med 1999;13:153-158.
48. Lemke DM, Hacein-Bey L. Metastatic compression fractures-vertebroplasty for pain control. J Neurosci Nurs 2003;35:50-55.
49. Ray Jr CE. Interventional radiology in cancer patients. Am Fam Physician 2000;62:95-102.